Who we are
UPO (www.uniupo.it) is a public University that has 15,000 students, 400 professors/researchers and 300 administrative and support staff. It offers 19 undergraduate courses (BA/BSc), 12 2-year undergraduate courses (MA/MSc), 5 Single Cycle Degrees (MA/MSc), 3 Ph.D. programs as well as a plethora of tertiary education courses. At present there are 9 agreements for joint programmes with European Universities, including the European Masters in Drug and Alcohol Studies (EMDAS) funded by the European Commission. The University has been recently ranked 5th out of 31 mid-sized Universities in 2017 by the national agency for the evaluation of quality for its research. UPO is at present involved in 21 FP7 Projects (1 ERC grant) and 9 H2020 Projects (2 as Coordinator).
The Department of Pharmaceutical Sciences (www.dsf.uniupo.it; DSF) is composed of 35 staff members and focuses its research and training objective around drugs, cosmetics and nutraceuticals, from bench to bedside. It offers a degree in Pharmacy, a degree in Chemistry and Pharmaceutical Technologies and a Master programme in Regulatory Sciences and Market Access. Its researchers in the past 3 years have secured two grants from the European Union: TriforC (Prof. Appendino, in the natural products area) and Foodintegrity (in the nutraceutical field). It has over 100 agreements with pharmaceutical and cosmetic industries for secondments. At present, there are 5 spin-offs generated by the Department.
UMH (www.umh.es/) is a public University dedicated to the training of undergraduate and postgraduate students. In the fifth edition of the U-Ranking of Spanish Universities produced by the BBVA Foundation and the Valencian Institute of Economic Research (IVIE), UMH occupies the 5th position in the ranking of best Spanish Universities.
The Institute of Molecular and Cellular Biology, IBMC (ibmc.umh.es/) drives a multidisciplinary translational programme of excellence at molecular and cellular level aimed at identifying, validating and developing bioactive molecules with application in the fields of biotechnology and health. For achieving its objective, IBMC has all the support for entrepreneurial activities through the Quorum Foundation in the Scientific Park. Moreover, the Institute has assembled several technological platforms: i) Biological High Throughput Screening Platform; ii) Molecular Modelling Platform; iii) Skin Research Platform (SRP), a public-private initiative whose mission is to conduct molecular and cellular research in all aspects related to skin to develop technologically advanced products and services in the cosmetic and dermatological field.
The IBMC research groups are internationally competitive, with an excellent productivity also in terms of patent applications and creation of Spin-off companies. In the last five years IBMC has obtained resources valued at € 1.5M on average, principally from the National Plan for R&D&I of the former Ministry of Science and Innovation (65%) and contracts with private companies (23%), which denotes a high level of competitiveness. IBMC coordinates a €6.0M allotment over five years as part of a CONSOLIDER-INGENIO 2010 project. IBMC partners include Lipotec, GP Pharma, Centro Demológico de Alicante and BioArray.